In contrast, our investigation provides deeper insights, revealing that the anti‐OSA effects of silencing SQLE were achieved through depleting cholesterol and subsequently inhibiting the FAK/PI3K/Akt/mTOR signalling pathway. The gene discussed is PTK2; the disease is obstructive sleep apnea syndrome.